Dermira (NASDAQ:DERM) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Monday, February 5th.
Other analysts also recently issued research reports about the stock. Leerink Swann reaffirmed an “outperform” rating and set a $41.00 price target (down previously from $47.00) on shares of Dermira in a report on Tuesday, November 7th. Guggenheim assumed coverage on shares of Dermira in a research report on Tuesday, December 5th. They set a “buy” rating for the company. Mizuho lowered their price objective on shares of Dermira from $43.00 to $39.00 and set a “buy” rating for the company in a research report on Tuesday, December 12th. Needham & Company LLC reiterated a “buy” rating and set a $43.00 price objective (down from $46.00) on shares of Dermira in a research report on Tuesday, November 7th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $45.00 price objective on shares of Dermira in a research report on Monday, November 6th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $42.17.
Shares of Dermira (NASDAQ DERM) opened at $28.62 on Monday. Dermira has a twelve month low of $21.35 and a twelve month high of $38.75. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 1.40.
In other Dermira news, SVP Christopher M. Griffith sold 18,458 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $27.05, for a total value of $499,288.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eugene A. Bauer sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $28.55, for a total transaction of $85,650.00. Following the completion of the transaction, the insider now owns 5,802 shares of the company’s stock, valued at $165,647.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 34,258 shares of company stock valued at $935,153. 13.30% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in DERM. Point72 Asset Management L.P. increased its position in Dermira by 621.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 712,904 shares of the biopharmaceutical company’s stock valued at $19,248,000 after acquiring an additional 614,138 shares during the period. Emerald Advisers Inc. PA acquired a new stake in shares of Dermira during the fourth quarter worth $14,918,000. BlackRock Inc. increased its position in shares of Dermira by 15.6% during the second quarter. BlackRock Inc. now owns 3,922,253 shares of the biopharmaceutical company’s stock worth $114,294,000 after buying an additional 529,405 shares during the period. State Street Corp increased its position in shares of Dermira by 38.4% during the second quarter. State Street Corp now owns 821,748 shares of the biopharmaceutical company’s stock worth $23,946,000 after buying an additional 228,093 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Dermira by 9.8% during the second quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock worth $40,735,000 after buying an additional 125,157 shares during the period. Hedge funds and other institutional investors own 97.84% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Dermira (DERM) Rating Lowered to Hold at BidaskClub” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/14/dermira-derm-rating-lowered-to-hold-at-bidaskclub.html.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.